April 29, 2024

Biodexa Secures Rights to Commercialize eRapa for Rare Cancer, Additional Indications

Biodexa Pharmaceuticals (Nasdaq: BDRX) has entered an agreement with Emtora Biosciences (Rapamycin Holdings Inc.) for the rights to eRapa under an exclusive, worldwide license to develop, manufacture, commercialize and advance eRapa. eRapa is an oral tablet formulation of rapamycin, which is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). The company’s… [Read More]
April 29, 2024

Prism Stocks making the biggest moves premarket: Tesla, Paramount, Domino’s, Southwest Airlines and more

Here’s a quick look at the corporate highlights making waves before the market opens: Tesla – The electric auto manufacturer’s shares catapulted by over 10% in premarket trading. This surge came after local regulatory bodies in China lifted previous limitations imposed on Tesla’s vehicles. Market watchers expect the firm’s advanced Full Self-Driving software to be… [Read More]
April 27, 2024

Tackling Glioblastoma: Five Companies Meeting Brain Cancer Head On

Glioblastoma is a complex, aggressive brain cancer that has no cure. The median length of survival following diagnosis is between 15 and 18 months, and the five-year survival rate sits at around 10%. More than 14,000 Americans receive a glioblastoma diagnosis each year. Glioblastoma tumors are notoriously difficult to treat, due to their location and… [Read More]
April 26, 2024

OHHH SNAP..the gains are not sneaky links

The App Snap and covert transmissions between creeping adults can no longer be synonymous with a bad moves or questionable acts of  indiscretion, at least for investors.  Finally, gains are being recorded and Snaps’ current position has investors seeing more than just ick. Snap Inc., the parent company of Snapchat, saw its shares soar by… [Read More]
April 26, 2024

Holidaze Season: Green Successes Cited by Most Cannabis Retailers On 4/20

U.S. cannabis retailers saw strong sales on April 20, the peak day for cannabis purchases, despite challenges from widespread e-commerce platform outages. According to reports from retailers, point-of-sale (POS) systems, and e-commerce operators, there was a significant uptick in revenue and customer traffic over the high holiday weekend. Despite some glitches with the Dutchie e-commerce… [Read More]
April 26, 2024

Vistagen Tackles Mental Fatigue with Investigational Nasal Spray

Biopharmaceutical company, Vistagen (Nasdaq: VTGN), is tackling mental fatigue with PH15, an investigational pherine nasal spray. The company has reported positive results from a Phase 2a pilot study of PH15, which has demonstrated statistically significant improvement of psychomotor impairment caused by mental fatigue. Vistagen’s study compared PH15 to placebo and caffeine in sleep-deprived study participants… [Read More]
April 26, 2024

Talkspace Expands Mental Health Offering to Additional Half Million Women

Behavioral health company, Talkspace (Nasdaq: TALK) will expand its comprehensive mental health offering to an additional 500,000 women through a partnership with speciality telemedicine company, Thirty Madison. The partnership is a significant step forward in improving access to mental health care for women who may face barriers to traditional in-person therapy. Talkspace will also connect… [Read More]
April 26, 2024

Capricor Therapeutics Advances Duchenne Muscular Dystrophy Candidate

`Capricor Therapeutics (Nasdaq: CAPR) has successfully completed a Type-B Chemistry, Manufacturing and Controls (CMC) meeting with the FDA to discuss next steps for the company’s Biologics License Application (BLA) submission for its lead asset CAP-1002 in the treatment of Duchenne muscular dystrophy (DMD). Capricor’s share price settled up 2.18% on Thursday, rising an additional 2.91%… [Read More]
April 26, 2024

Positive Topline Results for Immutep’s Head and Neck Cancer Treatment

Immutep Limited (Nasdaq: IMMP) has reported positive preliminary topline results from Cohort B of its TACTI-003 Phase 2b trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression. The combination therapy demonstrated an overall response rate of… [Read More]